JP2023526259A5 - - Google Patents
Info
- Publication number
- JP2023526259A5 JP2023526259A5 JP2022568820A JP2022568820A JP2023526259A5 JP 2023526259 A5 JP2023526259 A5 JP 2023526259A5 JP 2022568820 A JP2022568820 A JP 2022568820A JP 2022568820 A JP2022568820 A JP 2022568820A JP 2023526259 A5 JP2023526259 A5 JP 2023526259A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- amino acid
- modified immune
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024104P | 2020-05-13 | 2020-05-13 | |
| US63/024,104 | 2020-05-13 | ||
| PCT/GB2021/051158 WO2021229235A1 (en) | 2020-05-13 | 2021-05-13 | Method of treatment of cancer or tumour |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526259A JP2023526259A (ja) | 2023-06-21 |
| JP2023526259A5 true JP2023526259A5 (https=) | 2025-03-27 |
Family
ID=76098971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568820A Pending JP2023526259A (ja) | 2020-05-13 | 2021-05-13 | がんまたは腫瘍の治療の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230190802A1 (https=) |
| EP (1) | EP4149631A1 (https=) |
| JP (1) | JP2023526259A (https=) |
| CN (1) | CN116194472A (https=) |
| AU (1) | AU2021270378A1 (https=) |
| CA (1) | CA3178588A1 (https=) |
| WO (1) | WO2021229235A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| GB202205572D0 (en) * | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
| CN116449016A (zh) * | 2022-08-26 | 2023-07-18 | 成都益安博生物技术有限公司 | 一种食管癌的外周血tcr标志物序列及其检测试剂盒和应用 |
| GB202213050D0 (en) * | 2022-09-07 | 2022-10-19 | Adaptimmune Ltd | Method of treatment of gastroesophageal cancer |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| EP4659024A1 (en) * | 2023-01-31 | 2025-12-10 | Agilent Technologies, Inc. | Immunohistochemistry (ihc) mage-a4 scoring protocols and methods for aiding cancer treatments |
| CN120594199B (zh) * | 2025-08-06 | 2025-11-07 | 浙江省肿瘤医院 | Mhc-ii表达在胃癌免疫治疗疗效预测中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201616238D0 (en) * | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| JP7037577B2 (ja) * | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| WO2020049496A1 (en) * | 2018-09-05 | 2020-03-12 | Glaxosmithkline Intellectual Property Development Limited | T cell modification |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| WO2021144338A1 (en) * | 2020-01-14 | 2021-07-22 | Adaptimmune Limited | Method of treatment of cancer or tumour |
-
2021
- 2021-05-13 EP EP21727917.3A patent/EP4149631A1/en active Pending
- 2021-05-13 AU AU2021270378A patent/AU2021270378A1/en active Pending
- 2021-05-13 US US17/924,980 patent/US20230190802A1/en active Pending
- 2021-05-13 JP JP2022568820A patent/JP2023526259A/ja active Pending
- 2021-05-13 CN CN202180060911.1A patent/CN116194472A/zh active Pending
- 2021-05-13 CA CA3178588A patent/CA3178588A1/en active Pending
- 2021-05-13 WO PCT/GB2021/051158 patent/WO2021229235A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526259A5 (https=) | ||
| Miyauchi et al. | Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics | |
| US11446377B2 (en) | Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer | |
| Ye et al. | Clinical immunotherapy in pancreatic cancer | |
| JP2023528206A5 (https=) | ||
| JP2020525427A (ja) | 癌を処置するための方法 | |
| KR20220007593A (ko) | 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 | |
| JP2022532490A5 (https=) | ||
| US20230190802A1 (en) | Method of treatment of cancer or tumour | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| Miljkovic et al. | Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies | |
| Gaudreau et al. | Phase I/II trial of immunotherapy with durvalumab and tremelimumab with continuous or intermittent MEK inhibitor selumetinib in NSCLC: early trial report | |
| Murphy et al. | State of the art management of metastatic gastroesophageal cancer | |
| CN111867598A (zh) | 肿瘤免疫赋活剂 | |
| Sarkisian et al. | Current clinical trials in the treatment of advanced melanomas | |
| KR20250155054A (ko) | 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 | |
| US20260000757A1 (en) | Combination therapy for lung cancer | |
| JP2024513915A (ja) | 二重特異性ｔ細胞エンゲージャーの投与方法 | |
| JP2023513350A5 (https=) | ||
| EP4204592A1 (en) | Methods of treating cancer by administering a pd-1 inhibitor | |
| Castelo-Branco et al. | Promising immuno-oncology treatments beyond the 2018 Nobel prize | |
| de Jesus et al. | Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies | |
| WO2019096233A1 (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途 | |
| TW202517295A (zh) | 包含3,5-二取代苯炔基化合物與免疫檢查點抑制藥之癌症治療法 | |
| de Agostinho et al. | Immunotherapy |